Clinical study of gemcitabine combined with S-1 in the treatment of advanced biliary tract cancer / 中国基层医药
Chinese Journal of Primary Medicine and Pharmacy
; (12): 1683-1685, 2019.
Article
en Zh
| WPRIM
| ID: wpr-753671
Biblioteca responsable:
WPRO
ABSTRACT
Objective To evaluate the recent efficacy and safety of gemcitabine combined with S-1 in the treatment of advanced biliary tract cancer. Methods From August 2014 to May 2017,27 patients with advanced biliary tract cancer confirmed by pathology in the First People＇s Hospital of Zhengzhou received gemcitabine (1 000mg/m2 ,day 1 and 8) and S-1(80mg/m2,day 1-14) every three weeks.The recent efficacy and toxicities were observed after two cycles of chemotherapy.Results All of the 27 patients were evaluated,1 patient(3.7%) achieved CR,6 patients(22.2%) with PR,12 patients(44.4%) with SD,8 patients(29.6%) with PD.The total response rate was 25.9%(7/27),the disease control rate was 70.4%(19/27).The main toxicities were gastrointestinal reactions and myelosuppression,no chemotherapy-related death was observed.Conclusion Gemcitabine combined with S-1 in the treatment of advanced biliary tract cancer is safe and effect.
Texto completo:
1
Base de datos:
WPRIM
Idioma:
Zh
Revista:
Chinese Journal of Primary Medicine and Pharmacy
Año:
2019
Tipo del documento:
Article